National Cancer Institute (NCI) Program for Natural Products Discovery: Rapid Isolation and Identification of Biologically Active Natural Products from the NCI Prefractionated Library

Tanja Grkovic,* Rhone K. Akee, Christopher C. Thornburg, Spencer K. Trinh, John R. Britt, Matthew J. Harris, Jason R. Evans, Unwoo Kang, Susan Ensel, Curtis J. Henrich, Kirk R. Gustafson, Joel P. Schneider, and Barry R. O’Keefe*

Cite This: ACS Chem. Biol. 2020, 15, 1104−1114

ABSTRACT: An automated, high-capacity, and high-throughput procedure for the rapid isolation and identification of biologically active natural products from a prefractionated library is presented. The semipreparative HPLC method uses 1 mg of the primary hit fraction and produces 22 subfractions in an assay-ready format. Following screening, all active fractions are analyzed by NMR, LCMS, and FTIR, and the active principle structural classes are elucidated. In the proof-of-concept study, we show the processes involved in generating the subfractions, the throughput of the structural elucidation work, as well as the ability to rapidly isolate and identify new and biologically active natural products. Overall, the rapid second-stage purification conserves extract mass, requires much less chemist time, and introduces knowledge of structure early in the isolation workflow.

NATURE is an important resource for the discovery of new drugs and drug leads, with over half of all anticancer drugs based on chemical scaffolds isolated from plants, marine invertebrates, and microbes.1 However, despite their success as clinically used agents, compatibility issues that make natural product extracts challenging have reduced enthusiasm for high-throughput screening (HTS) of crude natural product libraries in targeted assay systems.2 In addition, after initial testing has been completed and activity confirmed, the process of compound isolation and identification is often slow and can increase the expense of screening support as (1) natural product extracts represent a mixture of compounds which can number up to hundreds of individual molecules and (2) bioassay-guided fractionation processes often include several iterations of fractionation and secondary screening. To improve the speed of hit identification, many natural product research laboratories are working with prefractionated natural product libraries.3 The use of prefractionated libraries reduces the complexity of individual test samples, simplifying the isolation and active principle identification effort and reducing screening support requirements. In addition, prefractionation can sequester nuisance compounds such as salts, tannins, and fatty acids and thus decrease the probability of false positive screening hits as well as improve the solubility of samples for liquid handling purposes.

The National Cancer Institute (NCI) Program for Natural Products Discovery (NPNPD) is a newly launched program for the NCI. The goals of the new initiative are to generate prefractionated samples (up to 1 000 000) for modern high-throughput screening technologies and to develop integrated analytical resources for the rapid isolation and structure elucidation of biologically active natural products. Recently, we...
published the development of chromatographic and automation procedures used in the generation of the NPNPD library of natural product fractions. The methodology is based on separation of the crude extract into seven fractions using solid-phase extraction (SPE) on C₈ media and water/methanol step gradients. Proof-of-concept studies assessed the fraction library for a range of properties such as recovery and distribution of material and biological activity in cell-based and cell-free assays. In brief, we found good separation of mass across all seven fractions, enhanced activity of fractions compared to the crude extract, sequestration of common nuisance compounds, and demonstrated efficient identification of minor biologically active natural products. An ultra-performance liquid chromatography coupled to high-resolution mass spectrometry (UPLC–HRMS) metabolomic analysis of the pilot library with a minimum total ion current height (baseline) setting of 1 × 10⁴ showed that each fraction can contain an average of 20 compounds. Thus, while the prefractionation process generates a simpler, less complicated natural product sample, each fraction is still a mixture of secondary metabolites and requires additional chromatography steps toward the identification of pure active compounds. Herein, we present a robust, rapid, and reproducible high-throughput HPLC-based second-stage method for further separation of the NPNPD fraction library and structural elucidation of the active principles.

The HPLC-based method chromatographically separates 1 mg of a primary SPE fraction on a C₁₈ reversed-phase column into 22 subfractions, collected in 96 deep-well plates (Figure 1). This format can accommodate four sample injections to be collected in one plate with wells 1A–1D used as injection sites. The rest of column one is left empty for assay controls with fraction collection starting in well A2. Total run time, including gradient recovery, is 15 min per injection, and depending on the size of the collection bed used, the method enables high-throughput secondary separation workflow. For example, the large plate-based fraction collector used in this work is capable of processing 48 samples in a single run to generate 1056 subfractions in an assay-ready format in approximately 13.5 hours (Supporting Information (SI) Figure S1). In an HTS context, this workflow is able to process 500 primary hits and provide in excess of 10,000 wells containing dried-down pure and semipurified compounds back to the screening lab in a two-week window at a quantity that yields a sufficient amount of subfractions for multiple secondary assays.

Following HTS, for the purpose of active principle structural elucidation, second-stage HPLC chromatography is repeated, and the active wells are analyzed by ¹H NMR, LCMS, and FTIR. To have confidence in the reproducibility of the system, during both the original screening and the repeat structural identification runs, chromatography standards covering a cLogP range of −1 to 4 are used every 9th injection. SI Figure S2 shows consistency of the separation of the standards on three identical HPLC systems in our laboratory as well as over time on a single column with over 250 injections. Precision was one of the crucial aspects of methods development in this work, as repeat HPLC separations used for structural elucidation may take place weeks or months after the original screening run and it was imperative to have the confidence in the reproducibility of the chromatography. The spectroscopic and spectrometric analytical data gathered on the active subfractions are then used to search in-house and commercially available databases of natural products to identify the structures responsible for the observed activity. This process is generally referred to as “dereplication” in the natural products community. While ¹H NMR, ⁵D NMR, MS, and MS/MS fingerprints are well-established and widely used techniques for the dereplication of natural products, we found FTIR to be equally valuable in the dereplication workflow. Modern IR instruments have a relatively small footprint, are sensitive (requiring only micrograms of sample), and provide a large data set across the spectroscopic range suitable for library generation and pattern matching. Overall, the active principle dereplication step combining different analytical techniques enables rapid identification of known compounds and introduces knowledge of active principle structural class early in the isolation workflow, notably in only two automated steps from the crude extract and consuming 1 mg of fraction material derived from the initial 250 mg of extract.

Figure 1. Summary of second-stage chromatography method used for the rapid, high-throughput isolation of natural products. Example depicts a representative HPLC run with fraction collection events and duty cycle analysis of a typical injection cycle shown. The gradient, represented as percentage acetonitrile, is shown in pink as well as UV absorbance traces at 254 nm (in blue), 280 nm (in green), and 320 nm (in orange).
RESULTS AND DISCUSSION

Throughput. To demonstrate proof-of-concept, 32 extracts that displayed activity against the NCI-60 human tumor cell line panel (NCI-60) were chosen from the NCI’s Natural Products Repository and prefractionated producing a total of 224 SPE fractions which were then tested in the NCI-60 one-dose assay at a concentration of 10 $\mu$g/mL. In total, 34 SPE fractions were significantly active defined as reaching the LC$_{50}$ level against at least three different cell lines and were prioritized for second-stage HPLC work (Figure 2A). The active fractions were then chromatographed on a semi-preparative HPLC column and 22 subfractions were collected from each run giving a total of 748 wells generated in approximately 10 h of instrument time. The mass in each well after second-stage HPLC was unknown, and the subfractions were tested at a nominal concentration of 1.1 $\mu$g/mL (see Materials and Methods for specific details on this calculation).

Notably, 1 mg injection of the primary SPE hit fraction generated sufficient material to do follow-up one-dose testing on the NCI-60 panel, which is essentially 60 separate assays. The results showed that 75 subfractions reached the LC$_{50}$ level against at least 3 different cell lines (Figure 2B). Four of the 34 fractions tested (11%) lost activity, which might be due to low testing concentration or decomposition of active principles during HPLC.

For active principle dereplication work, the entire HPLC run was repeated, and the 75 NCI-60 active subfractions were analyzed by $^1$H NMR (as well as $^1$H−$^1$H COSY and $^1$H−$^{13}$C HSQC if sufficient material was present), LCMS, and FTIR. Figure 3 shows the analytical spectra for the active subfraction sourced from the sponge Auletta sp. (NSC #C1065). Our prefractionation nomenclature designates the prefix M for prefractionated extracts sourced from marine organisms, followed by the numerical designation for the crude extract, the fraction, and the subfraction. Here, the active subfraction M1065_S_16, was sourced from the crude extract C1065, fraction 5, subfraction 16. The FTIR spectrum for M1065_S_16 showed a distinctive sharp band at 2125 cm$^{-1}$ indicative of an isocyanide group and a broad carbonyl stretch at 1670 cm$^{-1}$. The mass spectrometry data showed a sodium adduct ion [M + Na]$^+$ at m/z 365.2566 as well as loss of HCN group at m/z 316.2644 and an additional loss of NH$_2$CHO at m/z 271.2424. The $^1$H NMR spectrum showed two methyl doublets $\delta_H$ 0.89 (d, 3H, $J = 6.3$ Hz) and $\delta_H$ 0.85 (d, 3H, $J =$...
6.1 Hz), two methyl singlets $\delta H 1.27$ (s, 3H) and $\delta H 1.26$ (s, 3H), and two exocyclic methylene broad singlets at $\delta H 4.86$ and $\delta H 4.65$ indicative of an amphilectene-type diterpene reported from haplosclerid sponges. In addition, the $^1H$ NMR
Figure 3 depicts crucial spectroscopic and spectrometric features used to dereplicate the structure of 8-isocyano-15-formamido-11(20)-amphilectene (1) to be responsible for the activity of subfraction M1065_5_16. Using this approach on all of the hits, we found that most subfractions contained pure or semipurified compounds in quantities that enabled collection of high-quality analytical data and subsequent rapid dereplication of known compounds. In total, we dereplicated the structures of 28 known biologically active natural products as well as identified subfractions that contained new natural products (SI Figure S3). By standardizing the workflow and focusing on the active subfractions only, the approach presents a significant reduction in total instrument as well as dereplication time, resulting in a substantial decrease in hit identification timelines and introducing knowledge of structure early in the isolation workflow.

Second Stage HPLC Scale-up Exemplified by an Amino Alkanol-Producing Haliclona chrysa Extract. The crude extract from the sponge Haliclona chrysa (NSC #C17747) showed moderate NCI-60 activity with a GI50 value of 13.6 μg/mL and selectivity for melanoma and colon cell line panels. A single SPE fraction 4 showed significant NCI-60 activity at 10 μg/mL and following second-stage HPLC, NCI-60 activity was concentrated in subfraction M17747_4_7, which contained a single major metabolite. Interpretation of the analytical data from the small-scale 1 mg HPLC injection depicted in SI Figure S4 revealed the active principle to be a long chain alkene-type compound with hydroxy and amino substituents and a mass that did not match any published structure. To obtain enough material for full structural elucidation as well as NCI-60 five-dose testing, SPE fraction 4 was subjected to a scale-up HPLC purification. Our scale-up procedure is designed to have 5 mg of the fraction material repeatedly injected onto the HPLC column using the same gradient and collection conditions as the original 1 mg small-scale run and instead of 96 deep-well plates, repeat injections are collected in 16 mL tubes. The 10 mm diameter semipreparative columns used for both the small-scale and scale-up work showed excellent reproducibility between the 1 mg and 5 mg injections without the need for method scaling. By collecting successive injections into the same tube, the large bed capacity liquid handlers shown in Figure S1C are capable of processing hundreds of milligrams of material in a single run. Thus, the automated, high-capacity, and high-throughput extract processing procedure yields pure or semipurified natural products in only two automated chromatographic steps, requiring much less chemist time and conserving extract mass. Figure 4 shows a comparison of the active subfraction M17747_4_7 sourced from small-scale (1 mg) and scale-up (5 mg) HPLC purifications by 1H NMR demonstrating repeatability and consistency of the method. Here, we isolated a pure natural product (>95%) with sufficient material for structural elucidation and biological activity assessment in two chromatographic steps.

Subfraction M17747_4_7 yielded a pure new natural product, halaminol E (2), which was isolated as a weakly optically active amorphous solid with a molecular formula C_{16}H_{29}NO established by HRESIMS and 13C NMR measurements. The FTIR spectrum showed two distinctive sharp bands at 2925 and 2853 cm⁻¹ indicative of a primary amine group and a broad hydroxyl group stretch at 3000 cm⁻¹. The mass spectrometry data showed a protonated molecule [M + H]+ at m/z 252.23269 as well as loss of H₂O from the precursor ion at m/z 234.2218. The 1H and 13C NMR spectra in DMSO-d6 showed resonances associated with a terminal conjugated diene, one additional olefin, an oxymethine, an aminomethine, two well-resolved methylenes, a methylene envelope, and a terminal methyl doublet resonance. The 2-amino-3-hydroxy terminus was established via 1H-13C COSY and 1H-13C HMBC correlations from the terminal methyl at C-1 (δ_H 1.04, δ_1 6.6 Hz, δ_C 15.9) to the amino group at C-2 (δ_H 2.86, q, δ_1 6.7 Hz, δ_C 51.2), hydroxy group at C-3 (δ_H 3.77, t, δ_1 7.5 Hz, δ_C 73.6), a trans olefin at C-4 and -5 (δ_H 5.64, ddt, δ_1 15.4, 6.8, 0.9 Hz, δ_C 133.0, C-4); and δ_H 5.38, ddt, δ_1 15.4, 7.2, 1.4 Hz, δ_C 130.0, C-5), and an allylic methylene resonance at C-6 (δ_H 1.99, m, δ_C 31.6). A contiguous sequence of resonances from C-7 to C-12 (δ_H 1.34–1.25, δ_C 28.7–28.5) suggested the presence of a central methylene envelope. A conjugated diene terminus was established via 1H-13C COSY and 1H-13C HMBC correlations from the terminal olefinic methylene at C-16 (δ_H 5.09, ddt, J = 17.0, 2.0, 0.7 Hz, δ_C 4.95, ddt, J = 10.1, 2.1, 0.7 Hz, δ_C 115.1), which continued onto a series of three sp² hybridized methine resonances at C-15 (δ_H 6.29, ddt, δ_1 17.0, 10.1, 0.7 Hz, δ_C 137.2), C-14 (δ_H 6.04, m, δ_C 130.9), and C-13 (δ_H 5.72, ddt, δ_1 15.1, 7.0, 0.8 Hz, δ_C 135.3). The olefin at C-13 showed correlations to a methylene at C-12 (δ_H 2.05, m, δ_C 31.9) and the spin system continued onto the methylene envelope to complete the planar structure of the new natural product 2. Geometry of the Δ⁴ and Δ¹³ double bonds was established as E based on the magnitude of the vicinal coupling constants (J₁₅ = 15.4 Hz, J₁₃₁₄ = 15.1 Hz) and the downfield chemical shift of the allylic methylenes at C-6 (δ_C 31.6) and C-12 (δ_C 31.9). Based on structural similarities to other 2-amino-3-alkanols isolated from Haliclona sp. sponges, the new natural product 2 was given the trivial name halaminol E.

Recently, it was proposed that the absolute configuration of 2-amino-3-alkanols can be determined upon comparison of the specific rotation and 13C NMR shifts of their N,O-diacetyl derivatives with the sign of the rotation being indicative of the absolute configuration at C-2 and the chemical shift for the C-1 methyl being indicative of the relative configuration of the threeo and erythro diastereomers. The N,O-diacetyl halaminol E exhibited dextrorotatory specific rotation ([α]_D +15, c 0.2, CHCl₃; [α]_D +10, c 0.2, MeOH) consistent with the (2R) configuration.
configuration, while the $^{13}$C NMR chemical shift in chloroform-$d$ of the C-1 methyl group ($\delta_{\text{C}}$ 17.9) was consistent with a threo configuration, suggesting the absolute configuration of 2 to be (2R,3R). However, the review exemplified only one (2R,3R) analogue$^{13,14}$ with no $^{13}$C NMR shifts of its N,O-diacetyl derivative given for comparison, which prompted us to further examine the absolute configuration of halaminol E by semisynthetic methods. Reaction of 2 with 1,1$'$-carbonylidyimidazole afforded the oxazolidinone 3 in a good yield. The coupling constant between H-2 and H-3 of 7.4 Hz was consistent with a trans $\Delta^4$ oxazolidinone isomer,$^{15}$ as was a selective 1D NOE irradiation of H-3 that showed an enhancement of the H-1 methyl resonance indicative of the threo configuration of the natural product. Ultimately, the configurational assignment was confirmed via exciton coupled circular dichroism (CD) spectrum of the bis-N,O-di(2-napthoyl) derivative 4. Compound 4 was obtained by hydrogenation of 2 (H$_2$, Pd-C, MeOH), followed by a reaction with 2-napthoic acid$^{16}$ (EDC HCl, 2-napthoic acid, DMAP, 5 equiv each, CH$_2$Cl$_2$, rt). The CD spectrum of 4 (MeCN) showed two strong Cotton Effects [$\lambda$ 226 (Δ$\varepsilon$ 62.4) and $\lambda$ 243 (Δ$\varepsilon$ −66.5)] consistent with three- (2R,3R) configuration.$^{17}$ Notably, semisynthetic studies confirmed the absolute configuration proposed by the specific rotation and $^{13}$C NMR shifts comparison model$^{15}$ and halaminol E (2), is a rare naturally occurring (2R,3R) analogue in the 2-amino-3-alkanol series.

In NCI-60 activity testing, compound 2 exhibited low micromolar activity with a GI$_{50}$ value of 6.76 μM (Table 1 and Figures 5 and 6). Swinholide A ($^{\text{GI}_{50}}$ 0.03 μM) and swinholide B ($^{\text{GI}_{50}}$ 0.017 μM) were selected for active principle identification (Figure 6), in contrast to the two previous examples where the active subfractions contained pure compounds in a high yield, here they were comprised of a mixture of minor metabolites. To isolate the active principles, a scale-up study was conducted using 0.9 g of the crude extract. Following prefracionation, the active SPE fraction 6 was processed using the automated second-stage HPLC scale-up procedure (95 mg in 19 × 5 mg injections requiring 6 h of instrument time). For a comparison of small-scale and scale-up subfraction liquid chromatography UV–vis spectra, see SI Figure S17. The active fraction spectral fingerprints recorded for the small-scale (1 mg) injection were used to guide the isolation of pure compounds from subfraction M15373_6_15, which led to the identification of two natural products that were present in this subfraction, namely (−)-coelodiol (5) and 33-methyltetrahydroalchondramide (7). A comparison of the active subfraction $^1$H NMR fingerprints shown in Figure 5 demonstrates the efficacy of the dereplication approach. Except for the resonances at δ$_H$ 4.0–4.2 and 1.35–1.50, all other signals in the active subfraction spectrum could be assigned to the two pure compounds identified.

In total, H. sanguineus active subfractions yielded five compounds (5–9) with their activities, and isolated yields are presented in Table 1. The most active compound swinholide A (9) with an IC$_{50}$ value of 30 nM was only present in 0.017% yield of the crude extract and 1.67% yield of the subfraction. Notably, while the $^1$H NMR fingerprint was not sensitive enough to detect this compound in the subfraction, the LCMS fingerprint did (SI Figure S18) and was used as a guiding principle for the scale-up isolation. The two-step automated procedure was able to concentrate the effective amount of compound close to 100 times in the subfraction compared to what was available in the crude extract with further purification requiring only one additional step of chromatography. In the concentration of very potent minor natural products, we show ability to detect

| compound | GI$_{50}$ (μM) | yield of crude (%) | yield of subfraction (%) |
|----------|---------------|--------------------|--------------------------|
| 2        | 6.76          | 3.7                | 100                      |
| 5        | 6.76          | 0.12               | 23.33                    |
| 6        | 4.37          | 0.21               | 19.35                    |
| 7        | 0.40          | 0.09               | 17.78                    |
| 8        | 0.18          | 0.15               | 12.90                    |
| 9        | 0.03          | 0.017              | 1.67                     |

$^{\text{GI}_{50}}$ is the concentration of the drug that causes 50% growth inhibition and values represent the average calculated across all 60 cell lines. Reported yields were calculated based on the recovery of the isolated compound from the two-step scale-up procedure.
and isolate moderately active compounds that might have been undetected when screening crude extracts alone, or their activity masked by other more potent active principles. (−)-Coelodiol (5) and mycgranol (6) are orders of magnitude less potent than 33-methyltetrahydrohalichondramide (7), 33-methyldihydrohalichondramide (8), and swinholide A (9) and might have been missed if not for the drastic increase of the activity per unit mass going from the crude extract to the fraction shown in Table 1.

Conclusion. The NPNPD automated, high-capacity, high-throughput HPLC-based method for purification of natural product fraction mixtures is presented. The HPLC platform is capable of processing 48 samples in 14 h to generate 1056 subfractions in an assay-ready format. The resulting subfractions are pure or semipurified compounds, and for most the active principle structures could be elucidated using only 1 mg of the primary fraction. For prioritized hits of interest, we show an effective, automated, two-step scale-up procedure that is capable of processing hundreds of milligrams of material. A direct comparison of the new NPNPD methodology to more traditional natural products chemistry methods, used previously in the NCI Natural Products Branch, provided the following comparison of the isolation of an active agent from a marine organic extract. Using traditional methods to produce ∼50 mg of active compound took 4 purification steps and a total of 2−3 weeks. Using the NPNPD methods described here, purification of 45 mg to a similar level of purity (∼97%) required only 2 days. Overall, the rapid and repeatable second-stage purification conserves extract mass, requires much less chemist time, and introduces knowledge of structure early in the isolation workflow. As such, we believe this approach has the potential to significantly reduce natural-product-based active principle identification timelines, cost of screening, and enable faster outcomes for evaluating and identifying natural products in HTS.

■ MATERIALS AND METHODS

Extraction. All marine biota used in this work was extracted according to the procedure outlined in McCloud.21 Briefly, frozen specimens were centrifuged in approximately 3 L of deionized water to generate the aqueous extract after which the solid biota material was freeze-dried and soaked in a mixture of methanol and dichloromethane (1:1) overnight to generate the organic extract. All work presented here was conducted on the organic solvent extracts.

Prefractionation. Automated prefractionation was carried out with a customized positive pressure solid phase extraction (ppSPE) workstation (Tecan Freedom Evo) with two robotic arms working together to process 88 extracts in parallel. A portion of the organic solvent extracts (250 mg) was weighed into barcoded tubes and dissolved in 4.5 mL of MeOH/EtOAc/MTBE (6:3:1). Dissolved samples were adsorbed onto cotton rolls (1.27 cm × 3.81 cm) contained within an empty SPE cartridge, followed by freeze-drying to

Figure 5. NCI-60 screening and active principle identification summary for subfraction H. sanguineus extract. The active subfraction M15373_6_15 spectrum is compared to that of the two compounds isolated from this subfraction, namely (−)-coelodiol (5) and 33-methyltetrahydrohalichondramide (7). Resonances belonging to each of the two pure compounds 5 in red and 7 in blue are marked on the spectra of the subfraction mixture.
remove solvents. Precipitation was done on 2 g SPE cartridges (Thermo C8 SPE octyl, non-end-capped: 50 μm, 60 Å). Prior to precipitation, each SPE cartridge was equilibrated with three column volumes of MeOH/H2O (5:95). Seven fractions were collected using the following elution: fraction 1 MeOH/H2O (5:95), fraction 2 MeOH/H2O (1:4), fraction 3 MeOH/H2O (2:3), fraction 4 MeOH/H2O (3:2), fraction 5 MeOH/H2O (4:1), fraction 6 MeOH, and fraction 7 MeCN/MeOH (1:1). A controlled rate of elution (<10 mL/min) was maintained, and the elution solvents (8 mL) were collected in preweighed 10 mL polypropylene FluidIX 2D-barcoded tubes containing a linear barcoded protective jacket and dried at 20–35 °C using Genevac HT-12 high-performance centrifugal evaporation systems. The mass of each natural product fraction was determined using a BioMicroLab XL2000 weighing station.

**Second-Stage Semipreparative HPLC.** Semipreparative HPLC was done on a Gilson HPLC purification system equipped with a CX-281 liquid handler, a 322-binary pump, and a 172-photodiode array detector. A mass of 1 mg of fraction was injected in 100 μL of DMSO. HPLC separations were performed on a Phenomenex Onyx Monolithic C18 [100 × 10 mm] column at a flow rate of 3.8 mL/min with the following conditions: an initial isocratic hold at 70% H2O (0.1% formic acid)/30% CH3CN (0.1% formic acid) from 0 to 1.5 min, followed by a linear gradient to CH3CN (0.1% formic acid) over 7.5 min, an isocratic hold at CH3CN (0.1% formic acid) for 3.5 min, followed by a linear gradient back to 70% H2O (0.1% formic acid)/30% CH3CN (0.1% formic acid) from 12.5 to 13.5 min and a final isocratic hold for 1.5 min. For each HPLC run, 22 fractions were collected in 30 s increments between 1.5 and 12.5 min in 96-well deep-well plates. A standard chromatography mix (30 μL) consisting of 2 mg mL−1 solution of uracil, acetanilide, acetophenone, propiophenone, valerophenone, and hexanophenone in DMSO was injected every 9th run for the standard-second semipreparative gradient conditions. For each of the eight HPLC runs, 5 mg was injected, and 22 fractions were combined from each of the 8 runs. Subfraction 7 yielded 8.1 mg of halaminol E (2) (3.7% crude extract yield).

**Halaminol E (2).** Clear oil; [α]D = −71.2, [α]254 = −1.6, [α]405 = 0, [α]346 = −4, [α]436 = −4, [α]281 = −2.4, (c 0.5, MeOH); UV (MeOH) λmax (log ε) 227 (3.51) nm; IR (film) 3000, 2925, 2853, 1582, 1346, 1002, 896 cm−1; 1H NMR (600 MHz, dms-4d): δH 8.40 (1H, br s, OH-2), 6.29 (1H, ddt, J = 17.0, 10.1, 0.7 Hz, H-15), 6.04 (1H, m, H-14), 5.72 (1H, dtt, J = 15.1, 7.0, 0.8 Hz, H-13), 5.64 (1H, dd, J = 15.4, 6.8, 0.9 Hz, H-5), 5.38 (1H, ddd, J = 15.4, 7.2, 1.4 Hz, H-4), 5.09 (1H, dtt, J = 17.0, 0.7, 0.7 Hz, H-16a), 1.96 (1H, m, H-6), 1.34 (4H, m, H-7/-9/11), 1.25 (6H, m, H-8/-9/-10), 1.04 (3H, d, J = 6.6 Hz, H-1); 13C NMR (151 MHz, dms-4d) δC 137.2 (C-15), 135.3 (C-13), 130.3 (C-14), 130.0 (C-4), 115.1 (C-16), 73.6 (C-5), 51.2 (C-2), 31.9 (C-12), 31.6 (C-6), 28.7–28.5 (C-7/8/9/10/11), 15.9 (C-1); HRESIMS m/z [M + H]+ 252.3236 (calcd for C9H15NO, 252.3231).

**N-O-Diacetyl Halaminol E.** A (1:1) solution of pyridine and acetic anhydride (0.3 mL) was added to halaminol E (2) (3.3 mg, 13.2 μM) and stirred at RT under N2 for 18 h. The reaction mixture was dried under vacuum and then dissolved in 6.0 mL of CH2Cl2, which was partitioned successively with 1 M aq. NaOH (3 × 3 mL), then brine (3 × 3 mL) and water (3 × 3 mL). The organic layer was dried over anhydrous Na2SO4 and evaporated to give a white solid. Final purification was done by HPLC using a Phenomenex Onyx C8 [150 × 22.5 mm] column at a flow rate of 15 mL/min and eluting with a gradient solvent system from water (0.1% formic acid) to acetonitrile (0.1% formic acid) to give 1.8 mg of N-O-diacetyl halaminol E: white solid; [α]D = +15.2, [α]365 = +56.4, [α]405 = 36, [α]436 = +24, [α]456 = +12, [α]436 = +10, (c 0.5, CHCl3); [α]D = +10, [α]436 = +59, [α]456 = +38, [α]436 = +26, [α]456 = +12, [α]436 = +8, (c 0.5, MeOH); H NMR (600 MHz, chloroform-d): δH 6.51 (1H, dt, J = 17.2, 10.3 Hz, H-15), 6.04 (1H, m, H-14), 5.74 (1H, m, H-5), 5.70 (1H, m, H-3), 5.47 (1H, br d, J = 9.0 Hz, NH-2, 5.37 (1H, ddt, J = 15.4, 7.5, 1.3 Hz, H-4), 5.19 (1H, m, H-3), 5.09 (1H, br d, J = 17.0 Hz, H-16a), 4.95 (1H, br d, J = 10.2 Hz, H-16b), 4.20 (1H, m, H-2), 2.08 (3H, s, OAc-3), 2.06 (2H, m, H-12), 2.02 (2H, m, H-6), 1.96 (3H, s, NAc-2), 1.37 (2H, m, H-11), 1.35 (2H, m, H-7), 1.23–1.30 (6H, m, H-8/-9/-10), 1.11 (3H, d, J = 6.8 Hz, H-1); 13C NMR (151 MHz, chloroform-d) δC 170.0 (OOCCH3), 169.5 (NHCOCH3), 137.3 (C-15), 136.7 (C-3), 135.5 (C-13), 130.9 (C-14), 124.9 (C-4), 114.6 (C-16), 77.0 (C-3), 47.8 (C-2), 32.5 (C-12), 32.3 (C-6), 29.2–28.8 (C-7/-8/-9/-10/-11), 23.4 (OCH3), 21.3 (NHCOCH3), 17.9 (C-1); HRESIMS m/z [M + H]+ 336.25268 (calcd for C9H15NO4O3, 336.25332).

**Halaminol E Oxazolidinone (3).** Halaminol E (2) (3.8 mg, 15.1 μmol) was dissolved into 1.0 mL of dry CH2Cl2 and placed onto a magnetic stir bar. A solution of 1,1-carbonyldimidazole (2.9 mg, 18.2 μmol, 1.2 equiv) in 1.0 mL of dry CH2Cl2 was added into the reaction flask, and the reaction mixture was stirred for 2 h at RT. The reaction mixture was concentrated under vacuum, and the remaining residue was purified by HPLC on a Phenomenex Onyx C8 [100 × 10 mm] column at a flow rate of 3.8 mL/min and elution using a gradient solvent system from water (0.1% formic acid) to acetonitrile (0.1% formic acid) to give pure halaminol E oxazolidinone (3) (0.5 mg, 1.8 μmol): white solid; 1H NMR (600 MHz, DMSO-d6): δH 7.64 (1H, br s, NH-2), 6.29 (1H, dt, J = 17.0, 10.3 Hz, H-15), 6.04 (1H, dd, J = 15.3, 10.3 Hz, H-14), 5.81 (1H, m, H-5), 5.72 (1H, dt, J = 15.2, 7.0 Hz, H-13), 5.52 (1H, dtt, J = 15.3, 7.7, 1.5 Hz, H-4), 5.09
...Hz, 3H); HRESIMS ECD (CH3CN) (3H, d, 1.8 Hz), 7.66 (1H, m), 7.61 (1H, m), 7.57 (1H, m), 5.25 (1H, ddd, O), 3.12 (H, s), 2.74 (H, s). This material was carried through a silica gel SPE cartridge, followed by HPLC using a Phenomenex Onyx Monolithic C18 [100 μm] column at a flow rate of 15 mL/min with the following conditions: an initial isocratic hold at CH3CN/H2O (65:35) for 5 min, followed by a linear gradient to MeOH/H2O (85:15) over 45 min, and a final hold at MeOH/H2O (85:15) for 10 min, with fractions collected in 30 s increments starting from time = 0 min. Fraction 35 yielded 33-methyltetrahydrohalichondramide (7) (0.8 mg, 0.09% crude extract yield) and fraction 40 yielded 33-methyldihydrohalichondramide (8) (1.2 mg, 0.18% crude extract yield). Fractions 42–46 were combined and further purified on a Phenomenex Onyx Monolithic C18 [100 × 10 mm] with the following conditions: an initial isocratic hold at CH3CN/H2O with 0.1% formic acid (1:1) for 5 min, followed by a linear gradient to CH3CN over 45 min, and a final hold at CH3CN for 10 min, all at 10 mL/min and with fractions collected in 1 min increments starting from time = 0 min. Fraction 15 yielded swinholide A (9) (0.15 mg, 0.017% crude extract yield).

(→)-Coelodiol (5). Clear oil; [α]D = −6, (c 0.1, CHCl3); λ max NMR spectroscopic data in agreement to those previously reported for (+)-coelodiol;22 HRESIMS m/z [M + H]+ 351.25322 (calcd for C13H16O6, 351.25099).

Mycgranol (6). Clear oil; chiroptical and NMR spectroscopic data in agreement to those previously reported;23 HRESIMS m/z [M + Na]+ 875.44086 (calcd for C45H67N4O12Na+, 875.44129).

33-Methyltetrahydrohalichondramide (7). Clear oil; NMR spectroscopic data in agreement to those previously reported;24 HRESIMS m/z [M + H]+ 855.47518 (calcd for C45H66N4O12, 855.4750).

33-Methyldihydrohalichondramide (8). Clear oil; chiroptical and NMR spectroscopic data in agreement to those previously reported;25 HRESIMS m/z [M + Na]+ 875.44086 (calcd for C45H67N4O12Na+, 875.44129).

Swinholide A (9). Clear oil; λ max NMR spectroscopic data in agreement to those previously reported;26 HRESIMS m/z [M + Na]+ 1411.92072 (calcd for C65H102Na10O17, 1411.92042).

**ASSOCIATED CONTENT**

**Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschemicalbiology.0c00139.

Additional figures, NMR spectra, and NCI-60 five-dose graphs (PDF)

**AUTHOR INFORMATION**

**Corresponding Authors**

Tanja Grkovic – Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States; orcid.org/0000-0002-6537-3997; Phone: +1 301-846-5688; Email: tanja.grkovic@nih.gov

Barry R. O’Keefe – Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis and Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States; orcid.org/0000-0003-0772-4856; Phone: +1 301-846-5332; Email: okeefeba@nih.gov

https://dx.doi.org/10.1021/acschemicalbiology.0c00139

ACS Chem. Biol. 2020, 15, 1104–1114
**Authors**

Rhone K. Akee — Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

Christopher C. Thornburg — Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States; orcid.org/0000-0002-4657-6895

Spencer K. Trinh — Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

John R. Britt — Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

Matthew J. Harris — Natural Products Support Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

Jason R. Evans — Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States

Unwoo Kang — Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States

Susan Ensl — Department of Chemistry and Physics, Hood College, Frederick, Maryland 21701-8599, United States

Curtis J. Henrich — Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

Kirk R. Gustafson — Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States; orcid.org/0000-0001-6821-4943

Joel P. Schneider — Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States

Complete contact information is available at: https://pubs.acs.org/10.1021/acschemicalbio.0c00139

**Notes**

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Molecular Pharmacology Branch, DTP, DCTD, NCI for performing the NCI 60-cell cytotoxicity assays in support of this study. We also M. Dyba and S. Tarasov (Biophysics Resource, SBL, NCI) for assistance with the ECD measurements. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E, by the National Cancer Institute’s Cancer Moonsht12 and by the Intramural Research Program of the National Cancer Institute. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

■ REFERENCES

(1) Newman, D. J., and Cragg, G. M. (2016) Natural Products as Sources of New Drugs from 1981 to 2014. *J. Nat. Prod.* 79, 629–661.

(2) Henrich, C. J., and Beutler, J. A. (2013) Matching the power of high throughput screening to the chemical diversity of natural products. *Nat. Prod. Rep.* 30, 1284–1298.

(3) Harvey, A. L., Edrada-Ebel, R., and Quinn, R. J. (2015) The re-emergence of natural products for drug discovery in the genomics era. *Nat. Rev. Drug Discovery* 14, 111–129.

(4) Thornburg, C. B., Britt, J. R., Evans, J. R., Akee, R. K., Whitt, J. A., Trinh, S. K., Harris, M. J., Thompson, J. R., Ewing, T. L., Shipley, S. M., Grothaus, P. G., Newman, D. J., Schneider, J. P., Grkovic, T., and O’Keeffe, B. R. (2018) NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening. *ACS Chem. Biol.* 13, 2484–2497.

(5) Lang, G., Mayhedin, N. A., Mitova, M. I., Sun, L., van der Sar, S., Blunt, J. W., Cole, A. L. J., Ellis, G., Laatsch, H., and Munro, M. H. G. (2008) Evolving Trends in the Derelopment of Natural Product Extracts: New Methodology for Rapid, Small-Scale Investigation of Natural Product Extracts. *J. Nat. Prod.* 71, 1595–1599.

(6) Grkovic, T., Prouwer, R. H., Vial, M.-L., Gambini, L., Noël, A., Hooper, J. N. A., Wood, S. A., Mellick, G. D., and Quinn, R. J. (2014) NMR Fingerprints of the Drug-like Natural-Product Space Identify Iatrochodizine A: A Chemical Probe to Study Parkinson’s Disease. *Angew. Chem., Int. Ed.* 53, 6070–6074.

(7) Zhang, C., Idelbayev, Y., Roberts, N., Tao, Y., Nannapaneni, Y., Duggan, B. M., Min, J., Lin, E. C., Gerwick, E. C., Cottrell, G. W., and Gerwick, W. H. (2017) Small Molecule Accurate Recognition Technology (SMART) to Enhance Natural Products Research. *Sci. Rep.* 7, 1–17.

(8) Wang, M., Carver, J. J., Phelan, V. V., Sanchez, L. M., Garg, N., Peng, Y., Nguyen, D. W., Watrous, J., Kaponos, C. A., Luzzatto-Knaan, T., Porto, C., Bouslimani, A., Melnik, A. V., Meehan, M. J., Liu, W.-T., Crusemann, M., Boudreau, P. D., Eskenazi, E., Sandoval-Calderon, M., Kersten, R. D., Pace, L. A., Quinn, R. A., Duncan, K. R., Hsu, C.-C., Floros, D. J., Gavilan, R. G., Kleigrewe, K., Northen, T., Dutton, R. J., Parrot, D., Carlson, E. E., Aigle, B., Michelsen, C. F., Jelsbak, L., Sohlenkamp, C., Pevzner, P., Edlund, A., McLean, J., Piel, J., Murphy, B. T., Gerwick, L., Liaw, C.-C., Yang, Y.-L., Humpf, H.-U., Maasson, M., Keyzers, R. A., Sims, A. C., Johnson, A. R., Sidebottom, A. M., Sedio, B. E., Klütgaaard, A., Larson, C. B., Boya C., A., Torres-Mendoza, D., Gonzalez, J. D., Silva, D. B., Marques, L. M., Demarque, D. P., Pociute, E., O’Neill, E. C., Briand, E., Helrich, E. J. N., Granatosky, E. A., Glukhov, E., Ryfild, F., Houson, H., Mohimani, H., Kharbush, J. J., Zeng, Y., Vorholt, J. A., Kurita, K. L., Charusanti, P., McPhail, K. L., Nielsen, K. F., Vuong, L., Elfeki, M., Traxler, M. F., Engene, N., Koyama, N., Vining, O. B., Baric, R., Silva, R. R., Mascuch, S. J., Tomasi, S., Jenkins, S., Macherla, V., Hoffman, T., Agarwal, V., Williams, P. G., Dai, J., Neupane, R., Gurr, J., Rodríguez, A. M. C., Lamata, A., Zang, C., Dorrestein, K., Duggan, B. M., Almalti, J., Allard, P.-M., Phapale, P., Notihas, L.-F., Alexandrov, T., Litaudon, M., Wolferder, J., Kyle, J. E., Metz, T. O., Pereya, T., Nguyen, D.-T., Van Leer, D., Shinn, P., Jadhay, A., Muller, R., Waters, K. M., Shi, W., Liu, X., Zhang, L., Knight, R., Jensen, P. R., Palsson, B. O., Pogliano, K., Linnington, R. G., Gutierrez, M., Lopes, N. P., Gerwick, W. H., Moore, B. S., Dorrestein, P. C., and Bandeira, N. (2016) Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. *Nat. Biotechnol.* 34, 828–837.

(9) Ciavatta, M. L., Gavagnin, M., Manzo, E., Puliti, R., Mattia, C. A., Mazzarella, L., Cimino, G., Simpson, J. S., and Garson, M. J. (2005) Structural and stereoechemical revision of isocyanide and isothiocyanate amphiplenates from the Caribbean marine sponge *Cribichalina sp*. *Tetrahedron* 61, 8049–8053.
(10) Wratten, S. J., Faulkner, D. J., Hirotsu, K., and Clardy, J. (1978) Diterpenoid isocyanides from the marine sponge Hymeniacidon amphilecta. Tetrahedron Lett. 19, 4345–4348.

(11) Clark, R. J., Garson, M. J., and Hooper, J. N. A. (2001) Antifungal alkyl amino alcohols from the tropical marine sponge Haliclona n. sp. J. Nat. Prod. 64, 1568–1571.

(12) Pearce, A. N., Hill, C. A. E., Page, M. J., Keyzers, R. A., and Copp, B. R. (2019) An Acetylenic Lipid from the New Zealand Ascidian Pseudodistoma cereum: Exemplification of an Improved Workflow for Determination of Absolute Configuration of Long-Chain 2-Amino-3-alkanols. J. Nat. Prod. 82, 2291–2298.

(13) Gulavita, N. K., and Scheuer, P. J. (1989) Two epimeric aliphatic amino alcohols from a sponge. Xestospongia sp. J. Org. Chem. 54, 366–369.

(14) Mori, K., and Matsuda, H. (1992) Synthesis of sphingosine relatives. XII. Synthesis and absolute configuration of the two epimeric aliphatic amino alcohols [(5E,7E)-2-amino-5,7-tetradecadien-3-ols] isolated from a sponge, Xestospongia sp. Liebigs Ann. Chem. 2, 131–137.

(15) Pelt, R., Sames, D., and Chruma, J. (1999) Glycosidase inhibitors: synthesis of enantiomerically pure aza-sugars from Schiff base amino esters via tandem reduction-alkenylation and osmylation. J. Org. Chem. 64 (17), 6147–6158.

(16) Pearce, A. N., Copp, B. R., and Molinski, T. F. (2019) Enantiomeric variability of distaminolyne A. Refinement of ECD and NMR methods for determining optical purity of 1-amino-2-alkanols. Molecules 24 (1), 90–104.

(17) Molinski, T. F., Bieglmeyer, R., Stout, E. P., Wang, X., Frota, M. L. C., and Henriques, A. T. (2013) Halisphingosines A and B, Modified Sphingoid Bases from Haliclona tubifera. Assignment of Configuration by Circular Dichroism and van’t Hoff’s Principle of Optical Superposition. J. Nat. Prod. 76, 374–381.

(18) Cuadros, R., Montejo de Garcini, E., Wandosell, F., Faircloth, G., Fernandez-Sousa, J. M., and Avila, J. (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett. (N. Y., NY, U. S.) 152, 23–29.

(19) Baird, R. D., Kitzen, J., Clarke, P. A., Planting, A., Reade, S., Reid, A., Welsh, L., Lopez Lazaro, L., de las Heras, B., Judson, I. R., Kaye, S. B., Estens, F., Workman, P., de Bono, J. S., and Verweij, J. (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol. Cancer Ther. 8, 1430–1437.

(20) Massard, C., Salazar, R., Armand, J. P., Majem, M., Deutsch, E., Garcia, M., Oaknin, A., Fernandez-Garcia, E. M., Soto, A., and Soria, J. C. (2012) Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Invest. New Drugs 30, 2318–2326.

(21) McCloud, T. G. (2010) High throughput extraction of plant, marine and fungal specimens for preservation of biologically active molecules. Molecules 15, 4526–4563.

(22) Fattorusso, E., Romano, A., Taglialetela-Scafati, O., Barestrello, G., Bonelli, P., and Calcinai, B. (2006) Coelodiol and coeloic acid, ent-isocopalane diterpenes from the Indonesian sponge Coelocarteria cfr. singaporense. Tetrahedron Lett. 47, 2197–2200.

(23) Rudi, A., Benayahu, Y., and Kashman, Y. (2005) Mycgranol, a new diterpene from the marine sponge Mycale aff. graveleyi. J. Nat. Prod. 68, 280–281.

(24) Dalisay, D. S., Rogers, E. W., Edison, A. S., and Molinski, T. F. (2009) Structure Elucidation at the Nanomole Scale. 1. Trisoxazole Macrolides and Thiazole-Containing Cyclic Peptides from the Nudibranch Hexabranchus sanguineus. J. Nat. Prod. 72, 732–738.

(25) Matsunaga, S., Fusetani, N., Hashimoto, K., Koseki, K., Noma, M., Noguchi, H., and Sankawa, U. (1989) Bioactive marine metabolites. 25. Further kabiramides and halichondramides, cytotoxic macrodilides embracing trisoxazole, from the Hexabranchus egg masses. J. Org. Chem. 54, 1360–1363.

(26) Andrianasolo, E. H., Gross, H., Goeger, D., Musafia-Girt, M., McPhail, K., Leal, R. M., Mooberry, S. L., and Gerwick, W. H. (2005) Isolation of Swinholide A and Related Glycosylated Derivatives from Two Field Collections of Marine Cyanobacteria. Org. Lett. 7, 1375–1378.